在食道癌中的甲福明:探索分子机制和治疗见解
Stavros P Papadakos1, Alexandra Argyrou2, Vasileios Lekakis2
1First Department of Pathology, Medical School, National and Kapodistrian University of Athens, 75 Mikras Asias Street, Goudi, 11527 Athens, Greece.
International journal of molecular sciences
|March 13, 2024
概括
甲福明是一种抗糖尿病药物,通过影响关键代谢途径,显示出治疗食道癌 (EC) 的潜力. 研究表明,它可能有助于管理EC进展并改善患者的治疗结果.
科学领域:
- 在瘤学瘤学.
- 代谢医学是一种代谢医学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 食道癌 (EC) 存在重大治疗挑战和高死亡率.
- 创新的治疗策略对于改善EC患者的治疗结果至关重要.
- 一种常见的抗糖尿病药物梅特福明正在研究其抗癌性质.
研究的目的:
- 系统地审查和综合现有关于甲福明对食道癌影响的研究.
- 阐明在欧洲共同体中梅特福林潜在抗癌活性背后的代谢和分子机制.
- 评估梅特福林作为EC管理中的辅助疗法的临床和临床前证据.
主要方法:
- 系统分析关于甲福明和EC的各种科学研究.
- 对代谢途径和分子机制 (例如,胰岛素信号传递,AMPK,mTOR) 的全面审查.
- 批判性地检查流行病学,临床和临床前数据.
主要成果:
- 甲胺影响胰岛素信号传导,AMPK和mTOR等关键途径,可能抑制EC的进展.
- 有证据表明,甲福明可以调节炎症,氧化应激和血管生成.
- 综合数据支持甲福尔明在EC病原和管理中的潜在作用.
结论:
- 甲福明显示出与食道癌相关的多方面的抗癌作用.
- 需要进一步的研究和临床试验,以确定甲福尔明作为EC辅助疗法的有效性.
- 了解梅特福林的机制可能会为EC患者改善治疗策略和治疗结果.
相关概念视频
Oral Hypoglycemic Agents: Biguanides and Glitazones
199
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
199
Mitogens and the Cell Cycle
6.5K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.5K
Targeted Cancer Therapies
7.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.6K
Metastasis
5.5K
Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
5.5K
Electron Transport Chain: Complex I and II
13.2K
The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...
ROS generation is regulated and maintained at moderate levels necessary...
13.2K
Cancer Therapies
7.7K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.7K


